Here’s how the Medibank (ASX:MPL) share price has performed against the ASX200 in the last 3 months

Here’s how Medibank compares to the Index since 9 August…

| More on:
a man in a hospital bed on a drip gives a thumbs up sign while reclining with a bedside table containing a plant and fruit in the background.

Image source: Getty Images

How has the Medibank Private Ltd (ASX: MPL) share price performed against the S&P/ASX 200 Index (ASX: XJO) in the last 3 months? Good question!

The Medibank share price certainly didn’t have a pleasant start to the week today. It’s closed at $3.43 a share, down 1.3% for the day.

But how has it fared over the past 3 months? Well, back on 9 August, Medibank shares closed at a price of $3.41 each. That means Medibank shares have gone almost nowhere over the past 3 months (well, a gain of 0.59%) going off those bookend dates.

But that’s not to say the share price did nothing that whole time. In fact, on 7 September, the company hit a new 52-week high of $3.62 a share. By the back end of October, this private health insurance giant descended as low as $3.32 a share. That’s a difference of around 8.3%.

You can see this visually represented in the graph below:

Medibank share price
Medibank Private 3-month share price graph & data | Source: fool.com.au

But, as it turns out, this particular 3 month period has resulted in the Medibank share price going nowhere. That’s just how these things work sometimes. So how did the ASX 200 perform by comparison?

Well, the ASX 200 closed at 7,538.4 points back on 9 August. Today, it finished up at 7,452.2 points, a drop of 1.14% over the same period. Suddenly, Medibank’s anaemic performance over this period doesn’t look quite so bad, seeing it was still a market-beating investment.

Saying that, there was another silver lining for Medibank shareholders during this period. On 30 September, Medibank paid out its final dividend for FY21, a 6.9 cents per share payment, fully franked. This dividend in itself is worth a yield of roughly 2% on today’s pricing, so shareholders had that to bank over the past 3 months as well.

Medibank Private share price snapshot

Whilst Medibank has had a rather uninspiring 3 months, its longer-term performance is far more robust. Year to date, Medibank shares are up a healthy 13.95%, outperforming the ASX 200’s 11.49% performance over the same period. Over the past 12 months, Medibank shares are also up by 26.1%, again beating the ASX 200’s 20%.

At Medibank Private’s closing price of $3.43 today, this ASX 200 company has a market capitalisation of $9.45 billion, with a trailing annual dividend yield of 3.7%.

Should you invest $1,000 in Medibank Private right now?

Before you consider Medibank Private, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Medibank Private wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Imugene (ASX:IMU) share price leaps 10% on new Roche deal

Key Points Imugene shares rocket on back of new supply agreement with Roche Clinical trial of PD1-Vaxx will be combined …

Read more »

Lab technician analyses a sample in a laboratory for a clinical trial
Healthcare Shares

Race Oncology (ASX:RAC) share price rises following preclinical discovery

Key points The Race Oncology share price is up as high as 2.8% today A new discovery relating to heart …

Read more »

shocked man with hands over his face with a declining graph in background representing falling CleanSpace share price
Healthcare Shares

Why the AnteoTech (ASX:ADO) share price is plummeting 23% on Friday

Key Points AnteoTech shares sink on additional request for information by the TGA The company submitted a performance report last …

Read more »

Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx
Healthcare Shares

Why the Imugene (ASX:IMU) share price advanced 5% on market open

Key points Imugene share price soared 5% on the back of European patent approval This is further intellectual protection for …

Read more »

A healthcare worker wearing a white coat holds his fingers to his mouth looking worried as healthcare stocks like Cochlear crash today
Earnings Results

ResMed (ASX:RMD) share price on watch after Q2 update disappoints

Key points ResMed delivered solid revenue and profit growth in the second quarter A major competitor product recall boosted demand …

Read more »

Lab worker puts hands in the air and dances around
Healthcare Shares

Here’s why the Rhythm Biosciences (ASX:RHY) share price soared 8% today

Key points The Rhythm Biosciences share price finished the day up by more than 8% after earlier jumping by 19% …

Read more »

gloved hand holding covid-19 vaccine against backdrop of australian flag
Healthcare Shares

Own CSL (ASX:CSL) shares? Here’s why the company is moving on from COVID research

CSL Limited (ASX: CSL) shares are joining the broader ASX selloff today, down 3.93% to $248.20 per share. The S&P/ASX …

Read more »

Graph showing a fall in share price.
Healthcare Shares

Why is the Cochlear (ASX:COH) share price tumbling 5% on Thursday?

Key points Cochlear is one of the worst performing ASX 200 healthcare stocks on Thursday Right now, its share price …

Read more »